急性脑梗死患者血脂、脂蛋白、载脂蛋白与C反应蛋白的相关性研究

目的研究急性脑梗死患者血脂、脂蛋白、载脂蛋白与C反应蛋白的相关性,探讨急性期脑梗死患者血脂、脂蛋白、载脂蛋白水平与炎症反应的关系。方法将105例急性脑梗死患者抽取清晨空腹静脉血送检血脂、脂蛋白、载脂蛋白与C反应蛋白,分别作甘油三酯、总胆固醇、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)、极低密度脂蛋白(VLDL)、载脂蛋白AI(apoAI)、载脂蛋白B(apoB)、载脂蛋白B/载脂蛋白AI(apoB/apoAI)与C反应蛋白相关性分析。结果 HDL、LDL、VLDL、甘油三酯、总胆固醇、apoB与C反应蛋白无显著相关性,apoAI与C反应蛋白呈负相关(r=-0.22,P<0.05),apoB/apoAI与C反应蛋白呈显著正相关(r=0.34,P<0.01)。结论 apoAI、apoB/apoAI与炎症反应有关,可以将apoAI和apoB/apoAI与C反应蛋白共同检测,作为防治脑梗死的参考指标。     

辛伐他汀对高脂血症患者载脂蛋白E的影响

目的探讨辛伐他汀对高脂血症患者血清总载脂蛋白E(apoE)水平的影响。方法40例高脂血症患者每晚顿服辛伐他汀10mg4周,比较服药前后血清甘油三酯(TG)、胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、apoA1、apoB、apoE及脂蛋白(a)〔Lp(a)〕水平的变化。结果用药后血清TC及TG分别下降21．3％及9．2％(P<0．001,<0．05),LDL-C下降24．7％(P<0．01),apoB及apoE分别下降13．8％及34．7％(P<0．05,<0．001),apoA1增加7．5％(P<0．05)。apoE下降幅值分别与其自身基础值和TG及LDL-C基础值呈正相关(P<0．01,<0．01,<0．05)。HDL-C呈增高趋势,Lp(a)改变无统计学差异。结论辛伐他汀能导致血清apoE水平显著下降其可能参与了抗动脉粥样硬化过程。     

高血压病患者血清脂蛋白、载脂蛋白异常与胰岛素抵抗的关系

目的：探讨高血压病患者血脂／载脂蛋白异常与胰岛素抵抗的关系。方法：以空腹胰岛素／空腹葡萄糖比值和口服葡萄糖负荷后胰岛素曲线下面积／葡萄糖曲线下面积比值作为胰岛素抵抗指标，与空腹血脂／载脂蛋白进行直线相关分析。结果：与正常对照组（ｎ＝２１）比较，高血压病组（ｎ＝３２）血清甘油三酯（ＴＧ）、低密度脂蛋白胆固醇（ＬＤＬ－Ｃ）、载脂蛋白（Ａｐｏ）Ｂ、空腹胰岛素、空腹胰岛素／空腹葡萄糖比值以及胰岛素曲线下面积、葡萄糖曲线下面积和胰岛素曲线下面积／葡萄糖曲线下面积比值均显著增加（Ｐ＜０．０５～０．００１），高密度脂蛋白胆固醇（ＨＤＬ－Ｃ）、ＨＤＬ２－Ｃ、ＡｐｏＡＩ及ＡｐｏＡＩ／ＡｐｏＢ比值均显著降低（Ｐ＜０．０５～０．００１）。高血压病组空腹胰岛素／空腹葡萄糖比值和胰岛素曲线下面积／葡萄糖曲线下面积比值均分别与甘油三酯、低密度脂蛋白胆固醇和ＡｐｏＢ呈正相关（Ｐ＜０．０５～０．０１），与ＨＤＬ２－Ｃ、ＡｐｏＡＩ和ＡｐｏＡＩ／ＡｐｏＢ比值呈负相关（Ｐ＜０．０５～０．００１）。正常对照组上述指标间则无相关（Ｐ＞０．０５）。结论：高血压病患者血脂／载脂蛋白异常与胰岛素抵抗密切相关。     

Ⅱ型糖尿病并高血压患者胰岛素和脂蛋白水平的关系

目的：通过测定非胰岛素依赖型糖尿病（NIDDM）并高血压患者血中胰岛素浓度以了解高胰岛素血症与高血压脂蛋白代谢异常的关系。方法：配对观察高血压及无高血压糖尿病（HP－NIDDM组及NP－NIDDM组）各35例，行口服葡萄糖耐量和胰岛素释放试验，并与30例正常人（对照组）进行比较，分别测空腹，30、60、120、180min血糖及胰岛素水平，计算出胰岛素曲线下面积，三组均测血浆甘油三酯（TG）、胆固醇（TC）、高密度脂蛋白（HDL）、低密度脂蛋白（LDL）、载脂蛋白AI（apoAI），载脂蛋白B（apoB）及糖化血红蛋白（HbAic）。结果：HP－NIDDM组的体重指数（BMI）、TC、TG、LDL、apoB和HbAic高于对照组，HDL、apoAI低于对照组（均P＜0．05），TG、LDL、apoB和HbAic高于NP－NIDDM组，HDL、apoAI低于NP－NIDDM组（均P＜0．05），而BMI、TC及HbAic无统计学差异（均P＞0．05）；NP－NIDDM组的TC、TG、LDL和HbAic高于对照组，HDL低于对照组（均P＜0．05），余无统计学差异（均P＞0.05）。结论：HP－NIDDM患者存在胰岛素抵抗及高胰岛素血症与血脂apoAI、apoB关系密切。     

apoB基因EcoRI、XbaI位点和apoAI基因-75bp、＋83bp位点多态性的联合作用与哈萨克族人群血脂异常的关系

目的分析载脂蛋白B（apoB）基因EcoRI、XbaI位点和载脂蛋白AI（apoAI）基因一75bp、＋83bp位点多态性与哈萨克族人群血脂异常的关系。方法采用聚合酶链式反应-限制性片段长度多态性分析法检测225例哈萨克族血脂异常患者和187例哈萨克族正常对照者各个位点多态性,并分析其多种联合与血脂异常之间的关系。结果（1）两组各基因型联合的总体分布不同（P〈0．05）,基因型联合7频率在两组之间比较（19．1％vs11．2％）差异有统计学意义（P〈0．05）。（2）血脂异常组中基因型联合7的患者apoB、甘油三酯、总胆固醇水平显著高于其余基因型联合（联合1～6）的平均水平,apoAI、apoAI／apoB水平显著低于其余基因型联合的平均水平;同时此类患者的LDL—C显著低于基因型联合4,apoAI／apoB显著高于基因型联合4;而且其apoAI／apoB、HDL-C显著低于基因型联合1。（3）对照组基因型联合7的HDL-C、apoAI／apoB显著低于基因型联合1—6的平均水平,LDL—C显著高于基因型联合1～6平均水平;其HDL．C、apoAI／apoB显著高于基因型联合4;apoAI／apoB显著低于基因型联合1。结论基因型联合7与新疆石河子地区哈萨克族人群血脂异常相关,其机制可能与基因变异引起apoB、apoAI／apoB的变化等有关,且血脂紊乱可能始于基因变异引起的apoAI／apoB的变化。基因型联合4可能与哈萨克族人群血脂异常相关,基因型联合1可能预防血脂异常的发生。     

雌激素替代治疗对绝经后妇女冠心病血糖、血脂等的影响

目的：探讨雌激素对血糖、血胰岛素及血脂的影响。方法：对绝经后女性冠心病（CHD）60例，正常对照组30例做75g糖耐量试验，测空腹、餐后1．2小时血糖，血胰岛素（INS）及血脂（ISI），计算胰岛素敏感指数。CHD 组给予利维受（每片含7－甲异炔诺酮2.5mg）治疗12周，然后重复上述各项目检测。结果：与对照组相比，CHD组血糖、INS及ISI均有显性差异（P＜0．001）。利维爱治疗后，血糖、INS、总胆固醇、低密度脂蛋白胆固醇、载脂蛋白B较治疗前降低，而ISI、高密度脂蛋白胆固醇、载脂蛋白A水平升高，治疗前、后有显性差异（P＜0．001）。结论：雌激素替代治疗可以降低绝经后CHD患的血糖、INS水平，降低胰岛素抵抗（IR），纠正脂质代谢紊乱。     

冠心病患者血清载脂蛋白检测的临床研究

目的探讨载脂蛋白A-Ⅰ（apoA—Ⅰ）、载脂蛋白B（apoB）及apoA—Ⅰ与apoB比值对冠心病（CHD）的诊断价值。方法以冠心病病人为研究对象，健康体检者作为对照组。空腹采血，测定血清中apoA—Ⅰ、apoB的含量。结果冠心病病人apoA—Ⅰ／apoB含量及apoA—Ⅰ及apoB的比值与对照组相比差异有非常显著性。结论可供进一步研究冠心病病人载脂蛋白的代谢情况，为冠心病病人的诊断治疗提供了更有意义的预测指标。     

冠心病患者血浆小、密低密度脂蛋白的测定及其临床意义

目的观察冠心病患者血浆小、密低密度脂蛋白(sdLDL)和脂类成分的变化及相互关系。方法采用2％～16％非变性聚丙烯酰胺梯度胶电泳和凝胶成像分析,测定105例冠心病患者和76例健康对照者血浆sdLDL．同时测定血脂。结果sdLDL>50％的检出率,冠心病组为38．1％,对照组为10．5％(P<0．001);sdLDL增多患者的甘油三酯(TG)水平[(2．42±1．24)mmol／L]明显高于sdLDL正常者[(1．48±0．64)mmol／L](P<0．001)。结论sdLDL与冠心病发生发展有关,且与TG关系密切;sdLDL测定可作为预测冠心病危险性的指标之一。     

代谢综合征合并冠心病患者血浆P-选择素水平与胰岛素抵抗的关系

目的:探讨代谢综合征(MS)及合并冠心病(CHD)患者空腹血浆P-选择素水平和胰岛素抵抗及MS其他指标的相互关系。方法:用液相蛋白芯片结合流式细胞仪测定单纯MS组(17例)、MS CHD组(40例)和正常对照组(19例)空腹血浆P-选择素水平,用酶联免疫吸附法(ELISA)测定空腹血浆真胰岛素水平,并收集MS的其他有关数据:腰围、体重指数、空腹血糖和血脂,计算胰岛素敏感指数。结果:①P-选择素在正常对照组(25．1±3．6)μg／L,MS组(33．1±5．1)μg／L,MS CHD组(41．3±8．4)μg/L,3组间差异有显著性意义(F=37．54,P<0．05);②空腹血浆P-选择素水平与胰岛素敏感指数呈负相关(r=-0．460,P< 0．05),与体重指数(r=0．402,P<0．05)、低密度脂蛋白胆固醇(r=0．406,P<0．05)、腰围(r=0．538,P<0．05)、空腹真胰岛素(r=0．478,P<0．05)呈正相关;③以空腹血浆P-选择素水平为应变量的多元逐步回归分析提示,胰岛素敏感指数(r2=0．212)、腰围(r2=0．290)、空腹真胰岛素(r2=0．228)、低密度脂蛋白胆固醇(r2=0．165)、体重指数(r2=0．162)与P-选择素具有相关性(P<0．05)。结论:MS患者的P-选择素水平增加,合并CHD的MS患者更为明显,并与胰岛素抵抗相关,可能在MS发展为CHD中起一定作用。     

ApoB/ApoA1比值与代谢综合征的相关性研究

目的 探讨载脂蛋白B(ApoB)/载脂蛋白A1(APOA1)比值与代谢综合征(MS)及其组分的关系. 方法 纳入709例重庆地区成年人,测定体重、身高、血压、腰围、空腹血浆葡萄糖(FPG)、空腹血清胰岛素(FIns)及血脂等,计算ApoB/ApoA1、BMI及胰岛素抵抗指数. 结果 IR或MS患者,其ApoB/ApoA1比值显著增高;与低ApoB/APOA1值人群相比,高ApoB/ApoA1值人群发生MS(OR=3.5)和IR(OR=2.3)的风险显著增加(P<0.001).随MS组分数增加,ApoB/ApoA1比值逐渐增加(P<0.001). 结论 ApoB/ApoA1比值与IR、MS及其组分密切相关,ApoB/ApoA1比值增高是MS发生的重要标志.     

载脂蛋白B基因EcoRI、XbaI及载脂蛋白AI基因-75 bp、＋83 bp位点多态性与冠心病的关系

目的 分析载脂蛋白B（apoB）基因EcoRI、XbaI位点和载脂蛋白AI（apoAl）基因-75 bp、＋83 bp位点多态性与新疆石河子地区汉族人冠心病的关系.方法 采用聚合酶链式反应-限制性片段长度多态性分析法检测204例冠心病患者和132例正常对照者的apoB基因EcoRI、XbaI位点和apoAI基因-75 bp、＋83 bp位点多态性.结果 （1）冠心病组和对照组apoB基因EcoRl、Xbal位点和apoAI基因-75 bp、＋83 bp位点基因型及等位基因频率与新疆石河子地区汉族人冠心病发病无关.（2）冠心病组和对照组各基因型组合的总体分布不同（Х^2=23.497,P=0.024）,E^＋＋/X^＋-/M1^＋-/M2^＋＋及E^＋-/X1^--/M1^＋＋/M2^＋＋基因型组合频率在冠心病组和对照组的比值（9.3% vs 3%）比较差异有显著性（P＜0.05）.（3）冠心病组中E^＋＋/X^＋-/M1^＋-/M2^＋- 基因型组合的患者 apoB 水平高于冠心病组和对照组平均水平（P均＜0.01）,apoAI/apoB水平低于冠心病组或对照组平均水平（P均＜0.01）;冠心病组E^＋-/X^--/M1^＋-/M2^＋＋ 基因型组合的患者apoB水平高于冠心病组和对照组平均水平（P均＜0.05）,apoAI/apoB水平低于冠心病组或对照组平均水平（P均〈0.05）,且其TG、LDL-C高于对照组（P均〈0.05）.结论 apoB 基因EcoRl、Xbal位点和apoAI基因-75 bp、＋83 bp位点基因型联合中,E^＋＋/X^＋-/M1^＋-/M2^＋＋ 及 E^＋--/X^--/M1^＋-/M2^＋＋ 与新疆石河子地区汉族人冠心病相关,其中的机制可能与基因变异引起apoB、apoAI/apoB的变化继而引起血脂变化等有关.     

ApoB/apoA-I ratio: an independent predictor of insulin resistance in US non-diabetic subjects.

BACKGROUND: Recently, the apoB/apoAI ratio has been associated with the metabolic syndrome; however, is unclear if its association with insulin resistance is mediated through traditional risk factors or if it adds an independent risk by itself. The aim of this study was to assess the independent association between apoB/apoAI ratio and insulin resistance in the US non-diabetic population. METHODS: We examined the association between high apoB/apoAI ratio and insulin resistance among 2955 adults (mean age 47 years; 1457 women) without diabetes (fasting glucose < or =7 mmol/L and not taking diabetes medication), who participated in the Third National Health and Nutrition Examination Survey. Insulin resistance was estimated using the computer homeostatic model assessment (HOMA2) and defined as the upper quartile. The updated ATP-III definition of the metabolic syndrome was used. First, logistic regression was applied to estimate the cross-sectional association between apoB/apoAI (highest quartile vs. lowest quartile) and insulin resistance adjusting for metabolic syndrome components excluding glucose. Finally, multiple linear regression was used to assess the relationships between apoB/apoAI and insulin sensitivity. RESULTS: Overall, median of apoB/apoAI ratio was significantly higher in subject with insulin resistance than without (0.85, IQR 0.69-0.99 vs. 0.69, IQR 0.56-0.85; P < 0.0001). High apoB/apoAI ratio was independently associated with insulin resistance after adjustment for age and race, and remained significant after further adjustment for metabolic syndrome components, traditional and inflammatory risk factors (in men: OR, 4.12-95% CI, 1.97-8.81; in women: OR, 3.69-95% CI, 1.94-7.27). When apoB/apoAI was considered as a quantitative trait rather than dichotomized, use of the ratio improved the prediction of HOMA2 independently of metabolic syndrome components, traditional and inflammatory risk factors (in men: additional R(2) = 0.09, P < 0.001; in women: additional R(2) = 0.05, P < 0.001). CONCLUSION: In the US population, apoB/apoAI ratio is significantly associated with insulin resistance in non-diabetic subjects, independently of the traditional risk factors, metabolic syndrome components, and inflammatory risk factors. Important clinical risk information provided by apoB/apoAI ratio should be recognized and implemented in future clinical guidelines.     

2型糖尿病患者的脂代谢紊乱及其与冠心病的关系

目的：探讨2型糖尿病患脂代谢紊乱与并发冠心病（CHD）的关系。方法：56例2型糖尿病（DM）患（其中32例并发冠心病），测定其血脂、载脂蛋白浓度及血糖、胰岛素水平，与30例例健康人比较。结果：与对照组比较，2型DM并发CHD患高密度脂蛋白胆固醇（HDL－C）水平降低（P＜0．005），低密度脂蛋白胆固醇（LDL－C）及载脂蛋白B（ApoB)水平升高（P＜0．05）。单纯2型DM组仅有HDL－C水平的降低（P＜0．005）及LDL－C水平的升高（P＜0．05），无ApoB的变化，单纯DM及DM＋CHD组血糖及胰岛素水平无显差别，但均较对照组升高非常显（P＜0．005）；DM＋CHD组的ApoB水平较单纯DM组的显升高（P＜0．05）。结论：本组结果提示HDL－C水平的降低，LDL－C及ApoB水平的升高是2型DM并发冠心病的重要危险因素。     

Glucose tolerance, function of pancreatic B-cells and blood lipids in "healthy" offspring of parents with conjugal type 2 diabetes

In 56 adult normoglycemic nondiabetic (WHO criteria) subjects, whose both parents had type 2 diabetes, and in 68 control probants, matched for age, sex and body mass without family history of diabetes, the OGTT (75 g) was carried out, including measurement of serum insulin (IRI) and C-peptide (CP). In fasting state also the blood lipid profile was determined: serum triglycerides, total cholesterol, LDL-cholesterol, HDL-cholesterol, apolipoprotein AI (apoAI) and apolipoprotein B (apoB). In comparison with the control group, the offspring had significantly lower mean glycaemia on fasting, and non significantly elevated from the 60 min of the test, the significantly higher values of serum IRI and CP in fasting state and at the end of the test (120-180 min), and significantly lower serum CP:IRI molar ratio, expressing the reduced hepatic clearance of insulin. The offspring had significantly higher mean values of serum LDL-cholesterol, and significantly lower of serum HDL-cholesterol and apoAI, not disclosing significant differences in the serum levels of triglycerides, total cholesterol and apoB with the control group. Only serum HDL-cholesterol was significantly (negatively) correlated wit serum IRI and CP-values. The covariance analysis, eliminating the influence of age, body mass and the secretory activity of pancreatic B-cells, revealed the significant correlation of the presence of parental diabetes with serum levels of LDL-cholesterol (increase), and HDL-cholesterol and apoAI (decrease) in the offspring. These results prove indirectly, that in subjects genetically predisposed to type 2 diabetes, before the manifestation of glucose intolerance are present other effects of insulin resistance, expressed in increased activity of pancreatic B-cells, increased transfer of insulin to extrahepatic tissues, and in changes of concentration/composition of some lipoproteins dues to reduced influence of insulin on the enzymes which control their metabolism.     

2型糖尿病患者血管紧张素Ⅱ与胰岛β细胞分泌功能的关系探讨

目的 探讨不同糖耐量状态下血管紧张素Ⅱ与胰岛β细胞分泌功能的关系.方法 新诊断2型糖尿病患者42例(DM组)、空腹血糖受损/糖耐量受损者38例(IFG/IGT组)、正常对照者40名(NGT组)行静脉葡萄糖耐量试验,ELISA法测定空腹血管紧张素Ⅱ(AngⅡ)及脂联素水平.计算急性胰岛素分泌反应(AIR3-10)、第一时相(0～10min)胰岛素分泌曲线下面积(AUCⅠ)及峰值浓度、第二时相(10～120min)胰岛素分泌曲线下面积(AUCⅡ)、稳态模型评估胰岛β细胞功能指数(HOMA-β)及胰岛素抵抗指数(HOMA-IR).探讨AngⅡ与AIR3-10、AUCⅠ及峰值浓度、AUCⅡ、脂联素、HOMA-β及HOMA-IR的关系.结果 (1)DM组和IFG/IGT组AngⅡ显著高于NGT组(P＜0.05);DM组和IFG/IGT组AIR3-10、AUCⅠ及峰值浓度、AUCⅡ、脂联素显著低于NGT组(P＜0.05),DM组降低更为显著;(2)AngⅡ与AIR3-10、AUCⅠ及峰值浓度、AUCⅡ、脂联素、HOMA-β呈显著负相关(P＜0.01),与空腹血糖、糖负荷后2 h血糖、空腹胰岛素、HOMA-IR呈正相关(P＜0.05);(3)多元逐步回归分析,AngⅡ与AUCⅠ、AUCⅡ独立相关.结论 AngⅡ为胰岛β细胞分泌功能的独立影响因素.排除血压、体位、药物等因素的影响,高AngⅡ水平可预测2型糖尿病患者胰岛β细胞功能受损及胰岛素抵抗.

Abstract：

Objective To investigate the relationship between angiotensin Ⅱ and pancreatic islet β cell secretion function under different glucose tolerance statuses. Method Forty-two patients with newly diagnosed type 2diabetes mellitus ( DM group), 38 subjects with impaired fasting glucose/impaired glucose tolerance ( IFG/IGTgroup) ,and 40 normal control subjects (NGT group) underwent intravenous glucose tolerance test. Fasting plasma angiotensin Ⅱ ( Ang Ⅱ ) and adiponectin were assayed by ELISA. Acute insulin response from 3 to 10 min( AIR3-10 ),the area under the curve( AUCⅠ ) and the peak concentration of the first-phase ( 0-10 min) insulin secretion, the area under the curve of the second-phase( 10-120 min) insulin secretion( AUCⅡ), homeostasis model assessment for β cell function index(HOMA-β) and homeostasis model assessment for insulin resistance index(HOMA-IR) were calculated to explore the relationship with Ang Ⅱ. Result ( 1 ) The levels of Ang Ⅱ in DM group and IFG/IGT group were significantly higher than that in NGT group( P＜0.05 ). The AIR3-10, AUCⅠ and peak concentration, AUCⅡ ,adiponectin in DM group and IFG/IGT group were significantly lower than those in the NGT group ( P＜0. 05), and these results were more significantly reduced in DM group compared with those in IFG/IGT group. (2) Ang Ⅱ was negatively correlated with AIR3-10, AUCⅠ and the peak concentration, AUCⅡ, adiponectin, HOMA-β ( P＜0. 01 ), and positively correlated with fasting blood glucose,2 h blood glucose after glucose loading, fasting insulin, HOMA-IR (P＜0. 05 ). (3)Multiple stepwise regression analysis showed that Ang Ⅱ was independently associated with AUCⅠ and AUCⅡ.Conclusion Ang Ⅱ was an independent factor that affected the insulin secretion function of pancreatic islet βcells. Ruling out the effect of blood pressure, body position, drugs, and other factors, high levels of Ang Ⅱ could predict the dysfunction of pancreatic islet β cell as well as insulin resistance in patients with type 2 diabetes.     

Effect of xuezhikang,a cholestin extract,on reflecting postprandial triglyceridemia after a high-fat meal in patients with coronary heart disease

The effect of xuezhikang on postprandial triglyceride (TG) level was investigated in patients with coronary heart disease (CHD) after a high-fat meal (800 cal; 50 g fat). Fifty CHD patients were randomly divided into two groups to accept xuezhikang (xuezhikang group) 1200 mg/day (600 mg twice daily) or not (control group) on the base of routine therapy which included aspirin, metoprolol and fosinopril and nitrates during the whole 6 weeks following-up. Xuezhikang significantly reduced fasting serum total cholesterol (TC) (-20%), low-density lipoprotein cholesterol (LDL-C, -34%), TG (-32%) and apoB (-27%) levels, and raised fasting high-density lipoprotein cholesterol (HDL-C, 18%) and apoA-I (13%) levels (P<0.001). The postprandial serum TG levels at 2, 4 and 6 h decreased 32, 38 and 43%, respectively, in xuezhikang group (P<0.001). The TG area under the curve over the fasting TG level (TG-AUC) significantly decreased in CHD patients accepted xuezhikang with normal (less than 1.7 mmol/l) and elevated (1.74 to 2.92 mmol/l) fasting TG levels by 45 and 50%, respectively (P<0.001). Routine therapy had no significant effect on the fasting and postprandial lipid and apolipoprotein levels. The change of TG-AUC was significantly related to the changes of fasting TG, TC, LDL-C, and HDL-C levels after the treatment, which were related to the changes of fasting apoA-I and apoB levels significantly (P<0.001). Xuezhikang was shown to be beneficial in the treatment of reflecting postprandial triglyceridemia in CHD patients with normal and mildly elevated fasting TG levels.     

Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies

OBJECTIVES: To assess associations of circulating levels of apolipoprotein (apo) AI, apoB and the apoB/AI ratio (apoB/A) with risk of incident coronary heart disease (CHD). DESIGN: Literature-based meta-analysis of prospective studies. DATA SOURCES: Prospective studies in essentially general populations that reported on associations between apoAI, apoB or apoB/A and first incident CHD outcomes. Studies were identified by computer-based searches and by manual searches of the relevant literature. RESULTS: Data from 23 relevant studies were identified. For apoAI, with 6333 CHD cases in 21 studies, comparison of individuals in the bottom third with those in the top third of baseline values yielded a combined relative risk of 1.62 (95% confidence interval: 1.43-1.83), i.e. an inverse association. For apoB, a combined analysis of 6320 CHD cases from 19 studies gave a relative risk of 1.99 (1.65-2.39) for a comparison of individuals in the top third versus those in the bottom third of baseline values. For apoB/A, with 3730 CHD cases from seven studies, a comparison of individuals in the top third versus the bottom third of baseline values gave a combined relative risk of 1.86 (1.55-2.22). These associations were somewhat stronger following correction for within-person variations in apolipoprotein levels. There was evidence of heterogeneity amongst the published studies, but it was only partly explained by available study-level characteristics. CONCLUSIONS: The present quantitative review suggests the existence of moderately strong associations between baseline levels of each of apoAI, apoB, and apoB/A and risk of CHD. More detailed analysis, perhaps based on individual participant data from prospective studies, could help to overcome several limitations in the present review and to clarify any relevance of these apolipoproteins to disease prediction and aetiology.